medigraphic.com
ISSN 0188-9796 (Print)

2012, Number 3

<< Back Next >>

Rev Endocrinol Nutr 2012; 20 (3)

Pharmacological treatment of acromegaly

Mercado M

Language: Spanish
References: 90
Page: 120-130
PDF size: 288.75 Kb.


ABSTRACT

Acromegaly is a low-prevalence disease, caused in over 98% of the cases by a GH-secreting pituitary adenoma. The primary treatment of choice remains the transsphenoidal resection of the tumor. Postoperative remission rates as high as 85% can be found in patients harboring microadenomas o confined intrasellar macroadenomas, provided an expert pituitary neurosurgeon performs the procedure. In patients with macoradenomas, the likelihood of surgical success is around 40% in the best of cases. Thus, between 30 and 45% of patients with acromegaly will require an adjunctive form of therapy. Furthermore, it is increasingly evident that in many patients primary pharmacological treatment is indicated, either because of the size and/or location of their tumors makes surgical success very unlikely, or because of the presence of other medical conditions that would contraindicate surgery or simply because of patient and/or physician’s preference. In this review we cover the most relevant aspects of the pharmacological treatment of acromegaly with somatostatin analogs, dopamine agonists and GH receptor antagonists.


REFERENCES

  1. Fahlbusch R, Honegger J, Buchfelder M. Surgical management of acromegaly. Endocrinol Metab Clin North Am. 1992; 21: 669-692.

  2. Swearingen B, Barker FG, 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab. 1998; 83: 3419-3426.

  3. Espinosa-de-los-Monteros AL, Sosa E, Cheng S, Ochoa R, Sandoval C, Guinto G et al. Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease status. Clin Endocrinol (Oxf). 2006; 64: 245-249.

  4. Melmed S. Acromegaly: pathogenesis and treatment. J Clin Invest. 2009; 119: 3189-3200.

  5. Melmed S, Colao A, Barkan A et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009; 94: 1509-1517.

  6. Giustina A, Chanson P, Bronstein MD et al. A consensus on criteria for cure in acromegaly. J Clin Endocrinol Metab. 2010; 95: 3141-3148.

  7. Clemmons DR, Underwood LE, Ridgway EC, Kliman B, Kjellberg RN, Van Wyk JJ. Estradiol treatment of acromegaly. Reduction of immunoreactive somatomedin-C and improvement in metabolic status. Am J Med. 1980; 69: 571-575.

  8. Leung KC, Johannsson G, Leung GM, Ho KK. Estrogen regulation of growth hormone action. Endocr Rev. 2004; 25: 693-721.

  9. Dimaraki EV, Symons KV, Barkan AL. Raloxifene decreases serum IGF-I in male patients with active acromegaly. Eur J Endocrinol. 2004; 150: 481-487.

  10. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev. 2006; 27: 485-534.

  11. Barkan A, Bronstein M, Bruno OD, Cob A, Espinosa de los Monteros AL, Gadelha M, Garavito G, Guitelman M et al. Management of acromegaly in Latinamerica. Pituitary. 2010; 13: 168-175.

  12. Mayo KE, Miller T, DeAlmeida V, Godfrey P, Zheng J, Cunha SR. Regulation of the pituitary somatotroph cell by GHRH and its receptor. Recent Progr Horm Res. 2000; 55: 237-266.

  13. Tannenbaum GS, Epelbaum J, Bowers CY. Interrelationship between the novel peptide ghrelin and somatostatin/GHRH in the regulation of pulsatile GH secretion. Endocrinology. 2003; 144: 967-974.

  14. Brazeu P, Vale W, Burgus R, Ling N, Botheher M, Rivier J. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary GH. Science. 1973; 179: 77-79.

  15. Shimon I, Taylor JE, Dong JZ et al. Differential role of SSTR2 and SSTR5 for GH, TSH and PRL regulation. J Clin Invest. 1997; 99: 789-798.

  16. Yamada T, Soll AH, Park J, Elashoff J. Autonomic regulation of somatostatin release: Studies with primary cultures of canine fundic mucosal cells. Am J Physiol. 1984; 247: G567-G573.

  17. Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev. 1995; 16: 427-442.

  18. Patel YC. Molecular pharmacology of somatostatin receptor subtypes. J Endocrinol Invest. 1997; 20: 348-367.

  19. Pfeiffer M, Koch T, Schroder H et al. Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst3 receptor function by heterodimerization with sst2a. J Biol Chem. 2001; 276: 14027-14036.

  20. Pfeiffer M, Koch T, Schroder H et al. Heterodimerization of somatostatin and opioid receptors modulates phosphorylation, internalization and desensitization. J Biol Chem. 2002; 277: 19762-19772.

  21. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med. 1996; 334: 246-254.

  22. Chiodini PG, Cozzi R, Dallabonzana D, Oppizzi G, Verde G, Petroncini M et al. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine. J Clin Endocrinol Metab. 1987; 64: 447-453.

  23. Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2002; 87: 3013-3018.

  24. Sheppard MC. Primary medical therapy for acromegaly. Clin Endocrinol (Oxf). 2003; 58: 387-399.

  25. Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest. 1997; 100: 2386-2392.

  26. Jaquet P, Saveanu A, Gunz G, Fina F, Zamora AJ, Grino M et al. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab. 2000; 85: 781-792.

  27. Ren SG, Kim S, Taylor J, Dong J, Moreau JP, Culler MD et al. Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. J Clin Endocrinol Metab. 2003; 88: 5414-5421.

  28. Van der Hoek J, Lamberts SW, Hofland LJ. Precilinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas. European J Endocrinol. 2007; 156: s45-s51.

  29. Ferone G, de Herder WW, Pivonello R et al. Correlation of in vitro and in vivo somatotrophic adenoma responsiveness to somatostatin analogues and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocrinol Metab. 2008; 93: 1412-1417.

  30. Casarini AP, Pinto EM, Jallad RS, Giorgi RR, Gianella-Neto D, Bronstein MD. Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3. J Endocrinol Invest. 2006; 29: 826-830.

  31. Ho KY, Weissberger AJ, Merbach P, Lazarus L. Therapeutic efficacy of the somatostatin analogue SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency in long-term safety. Ann Intern Med. 1990; 112: 173-181.

  32. Newman CB, Melmed S, Snider TJ, Young WF, Boyajy LD, Levy R et al. Safety and efficacy of long-term octreotide teraphy of acromegaly: results of a multicenter trial in 103 patients-a clinical research center study. J Clin Endocrinol Metab. 1995; 80: 2768-2775.

  33. Heron I, Thomas F, Dero M et al. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab. 1993; 76: 721-727.

  34. Marek J, Hana V, Krsek M et al. Long-term treatment of acromegaly with the slow-release somatostatin analog lanreotide. Eur J Endocrinol. 1994; 131: 20-26.

  35. Attanasio R, Baldelli R, Pivonello R, Grottoli S, Bocca L, Gasco V et al. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab. 2003; 88: 5258-5265.

  36. Davies PH, Stewart SE, Lancranjan L, Sheppard MC, Stewart PM. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol. 1998; 48: 311-316.

  37. Espinosa-de-los-Monteros AL, Mercado M, Sosa E. Comparison of four and six week injection interval during treatment of acromegaly with octreotide LAR. Eur J Endocrinol. 2005; 252: s107.

  38. Biermasz NR, van den Oever NC, Frolich M, Arias AM, Smit JW, Romijn JA et al. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval. Clin Endocrinol. 2003; 58: 288-295.

  39. Turner HE, Thornton-Jones VA, Wass JA. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. Clin Endocrinol. 2004; 61: 224-231.

  40. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab. 2001; 86: 2779-2786.

  41. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab. 2002; 87: 4554-4563.

  42. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab. 2003; 88: 3090-3098.

  43. Bevan JS. The anti-tumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab. 2005; 90: 1856-1863.

  44. Caron P, Beckers A, Cullen DR, Goth MI, Gutt B, Laurberg P et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab. 2002; 87: 99-104.

  45. Chanson P, Boerlin V, Ajzenberg C, Bachelot Y, Benito P, Bringer J et al. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol. 2000; 53: 577-586.

  46. Amato G, Mazzioti G, Rotondi M et al. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol. 2002; 56: 65-71.

  47. Colao A, Cappabianca P, Caron P et al. Octreotide LAR versus surgery in newly diagnosed patients with acromegaly: a randomized, open-label multicentre study. Clin Endocrinol. 2009; 70: 757-768.

  48. Colao A, Pivonello R, Rosato F et al. First-line octreotide-LAR therapy induces tumor shrinkage and control hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol. 2002; 64: 342-352.

  49. Colao A, Pivonello R, Auriemma RS et al. Predictors of tumor shrinkage after primary therapy with somatostatin analogues in acromegaly: a prospective in 99 patients. J Clin Endocrinol Metab. 2006; 91: 2112-2118.

  50. Cozzi R, Montini M, Attanasio R et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab. 2006; 91: 1397-1403.

  51. Mercado M, Borges F, Bouterfa H et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol. 2007; 66: 859-868.

  52. Sosa E, Espinosa-de-los-Monteros AK, González B, Vargas G, Mercado M. Tratamiento de la acromegalia con octreótido LAR. Rev Med IMSS. 2008; 46: 205-212.

  53. Mendoza V, Sosa E, Espinosa-de-los-Monteros AL, Salcedo M, Guinto G, Cheng S. GSPα mutations in Mexican patients with acromegaly: potential impact on long-term prognosis. GH & IGF Res. 2005; 15: 28-32.

  54. Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab. 2005; 90: 6290-6295.

  55. Colao A, Attanasio R, Pivonello R et al. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2006; 91: 85-92.

  56. Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to somatostatin analogue. Clin Endocrinol. 2007; 67: 310-315.

  57. Carlsen SM, Lund-Johansen M, Schreiner T et al. Preoperative octreotide treatment in newly diagnosed patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab. 2008; 93: 2984-2990.

  58. Colao A, Ferone D, Lastoria S, Marzullo P, Cerbone G, Di Sarno A et al. Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab. 1996; 81: 2356-2362.

  59. Karavitaki N, Botusan I, Radian S, Coculescu M, Turner HE, Wass JA. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Clin Endocrinol. 2005; 62: 282-288.

  60. Hofland LJ, van der Hoek J, van Koetsveld PM et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab. 2004; 89: 1577-1585.

  61. Ma P, Wang Y, van der Hoek J et al. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM 230, with octreotide in patients with acromegaly. Clin Pharmacol Therap. 2005; 78: 69-80.

  62. Petersenn S, Schopohl A, Barkan A et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: A randomized, multicenter, phase II trial. J Clin Endocrinol Metab. 2010; 95: 2781-2789.

  63. Ramírez C, Vargas G, González B, Grossman A, Rábago J, Sosa E et al. Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: Is it worth trying? Eur J Endocrinol. 2012; 166: 21-26.

  64. Asa SL, Kovacs K. Pituitary pathology in acromegaly. Endocrinol Metab Clin North Am. 1992; 21: 553-574.

  65. Pivonello R, Matrone C, Filippella M et al. Dopamine expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J Clin Endocrinol Metab. 2004; 89: 1674-1683.

  66. Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Sarnacchiaro F et al. Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab. 1997; 82: 518-523.

  67. Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: A meta-analysis. J Clin Endocrinol Metab. 2011; 96: 1327-1338.

  68. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolensee JL et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab. 1998; 83: 374-378.

  69. Rocheville M, Lange DC, Kumar U, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science. 2000; 288: 154-157.

  70. Jaquet P, Gunz G, Saveanu A et al. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol. 2005; 153: 135-141.

  71. Gruszka A, Son-Guang R, Dong J, Culler MD, Melmed S. Regulation of growth hormone and prolactine gene expression and secretion by chimeric somatostatin-dopamine molecules. Endocrinology. 2007; 148: 6107-6114.

  72. Florio T, Barbieri F, Spaziante R et al. Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human, non-functioning pituitary adenomas: a multicentre study. Endocr Rel Cancer. 2008; 15: 583-599.

  73. Mercado M, DaVila N, McLeod JF, Baumann G. Distribution of growth hormone receptor messenger ribonucleic acid containing and lacking exon 3 in human tissues. J Clin Endocrinol Metab. 1994; 78: 731-735.

  74. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev. 2002; 23: 623-646.

  75. Kopchick JJ. Discovery and development of a new class of drugs: GH antagonists. J Endocrinol Invest. 2003; 26: 16-26.

  76. Ross RJ, Leung KC, Maamra M, Bennett W, Doyle N, Waters MJ et al. Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J Clin Endocrinol Metab. 2001; 86: 1716-1723.

  77. Maamra M, Kopchick JJ, Strasburger CJ, Ross RJ. Pegvisomant, a growth hormone-specific antagonist, undergoes cellular internalization. J Clin Endocrinol Metab. 2004; 89: 4532-4537.

  78. Veldhuis JD, Bidlingmaier M, Anderson SM, Wu Z, Strasburger CJ. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men. J Clin Endocrinol Metab. 2001; 86: 3304-3310.

  79. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000; 342: 1171-1177.

  80. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001; 358: 1754-1759.

  81. Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B et al. Tretament of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol. 2006; 156: 75-82.

  82. Trainer PJ. Acrostudy: the first 5 years. Eur J Endocrinol. 2009; 161: S19-S24.

  83. Biering H, Saller B, Bauditz J et al. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. Eur J Endocrinol. 2006; 154: 213-220.

  84. Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet. 2005; 365: 1644-1646.

  85. Neggers SJ, van Aken MO, Janssen JA et al. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab. 2007; 92: 4598-4601.

  86. Jorgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LO, Hagen C et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab. 2005; 90: 5627-5631.

  87. Drake WM, Rowles SV, Roberts ME, Fode FK, Besser GM, Monson JP et al. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur J Endocrinol. 2003; 149: 521-527.

  88. Jehle S, Reyes CM, Sundeen RE, Freda PU. Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly. J Clin Endocrinol Metab. 2005; 90: 1588-1593.

  89. Dekkers OM, Biermasz NR, Pereira AM, Romjin JA, Vandenbroucke JP. Mortality in acromegaly: a meta-analyisis. J Clin Endocrinol Metab. 2008; 93: 61-67.

  90. González B, Vargas G, Espinosa-de-los Monteros AL, Sosa E, Mercado M. Efficacy and safety of radiotherapy in a acromegaly. Arch Med Res. 2011; 42: 48-52.




2020     |     www.medigraphic.com